iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix

NASHUA, N.H., June 19 /PRNewswire-FirstCall/ -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, today announced it has initiated a clinical study for Colon CAD, its virtual colonoscopy CAD product, in p...

iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual Colonoscopy CAD Product

NASHUA, N.H., Jan. 22 /PRNewswire-FirstCall/ -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, today announced an agreement with ACR Image Metrix to conduct a multi-reader clinical study of iCAD's CT C...

ACRIN Study Endorses Virtual Colonoscopy - Validation for Colon CAD Software Maker Medicsight plc

NEW YORK, Oct. 3 /PRNewswire-FirstCall/ -- MGT Capital Investments, Inc. (Amex: MGT ), an investment company focused on the Healthcare Information Technology ("HCIT") sector, announced today that the ACRIN study endorses virtual colonoscopy for Medicsight PLC (subsidiary of MGT). Medicsight P...

SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine

...hether all patients with diabetes and multi-vessel cad might be better treated with optimal medical thera... the BARI-2D study enrolled a very small subset of cad patients with diabetes, SCAI looks forward to addi...owever, patients with type 2 diabetes mellitus and cad are at high risk for cardiovascular events, includ...

First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting

...t levels and reduction in hemolysis. Patients with cad suffer from an autoimmune attack on their red bloo...th eculizumab in a very limited number of aHUS and cad patients. These observations and other knowledge ...ts." Initial Experience with Eculizumab in cad A poster titled "Long-term Efficacy of the...

XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week

...focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). cad is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems...

Screening for Ischemia in Asymptomatic Patients With Type 2 Diabetes: Five- Year Outcomes in the DIAD Study

... to assess the prevalence of silent myocardial ischemia and discern whether cad screening should be offered to all people with type 2 diabetes. According t...verall, 1,123 diabetic patients without symptomatic or previously diagnosed cad were randomized to either screening with myocardial perfusion imaging or st...

XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention

...focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). cad is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems...

FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)

...ve in the SPECT dominated myocardial perfusion imaging market. The use of BFPET in conjunction with PET technology holds the promise to better quality cad diagnosis." About FluoroPharma FluoroPharma is a molecular imaging company engaged in the discovery and development of proprietary products for th...

Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format

...s shown to be associated with different degrees of cad risk. Over time, cad can weaken the heart muscle and lead to heart attack and arrhythmias. cad is the most common type of heart disease and is th...

XTENT Announces European Regulatory Update

...focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). cad is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems...

XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting

...focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). cad is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems...

XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week

...focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). cad is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems...

XTENT Announces First Quarter 2008 Financial Results

...focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). cad is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems...

FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)

...ery disease (CAD). BFPET, as a PET imaging tracer, may have a significant advantage due to its potential to improve the sensitivity and specificity of cad diagnosis and to provide information on myocardial mitochondrial damage. "This agent, if successful, should improve CAD diagnosis and follow-up of the...

FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)

...ET's continued safety in Phase II clinical trials. The PET technology we are studying today shows early promise and may hold the key to better quality cad diagnoses." Dr. Strauss is the Clinical Director of Nuclear Medicine at Memorial Sloan Kettering Cancer Center and Professor of Radiology at Cornell U...

Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection

...ogy Being Evaluated to Determine How Chest X-Ray cad Could Transform Common Radiological Procedure Into...n ongoing program to determine whether chest X-ray cad (computer-aided detection) can improve practical e...ogram is designed to determine whether chest X-ray cad can help identify hard to detect lung cancers at a...

XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System

...focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). cad is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems...

XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007

...focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). cad is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems...

ACC Presentation Indicates Interleukin-1 Gene Variants Determine Increased Risk for Coronary Artery Disease from Oxidized Phospholipids

...vels of OxPL or Lp(a) were associated with significantly increased risk for cad (P less than 0.01). This effect was strongly accentuated in patients less t...flammatory IL-1 genotypes, oxidation of phospholipids and predisposition to cad in younger individuals," said Sotirios Tsimikas, M.D., Associate Professor ...

Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal

...hown that the guidelines may not be universally effective at identifying a patients risk of cardiac events. In 1988, a study on cholesterol lipids and cad noted that 75 percent of patients who suffer myocardial infarctions have normal levels of HDL-C and LDL-C (Castelli, Can J Cardiol 1988 4A:5A). Thes...